证券代码：603676 证券简称：卫信康 公告编号：2023-029 西藏卫信康医药股份有限公司 第三届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2、审议通过了《2023 年半年度募集资金存放与实际使用情况的专项报告》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《2023 年半年度募集资金存放与实际使用情况的专项报告》。 公司独立董事对该议案发表了同意的独立意见。 表决结果：同意 7 票、反对 0 票、弃权 0 票。 3、审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》 一、董事会会议召开情况 西藏卫信康医药股份有限公司（以下简称"公司"）第三届董事会第七次会 议通知于 2023 年 8 月 11 日以邮件的形式送达全体董事。会议于 2023 年 8 月 22 日以现场和通讯表决相结合的方式召开。会议由公司董事长张勇先生主持，应出 席董事 7 名，实际出席董事 7 名。本次会议的参与表决人数及召开程序符合《公 司法》和《公司章程》的有关规定，合法有效 ...

西藏卫信康医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 30 日(星期三) 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadsh ow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 23 日(星期三)至 8 月 29 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过西藏卫信康医药股份有 限公司（以下简称"公司"）邮箱 wxk@wxkpharma.com 进行提问。公司将在信息 披露允许的范围内，在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 8 月 23 日发布公司 2023 年半年度报告，为便于广大投资 者更全面深入地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 8 月 30 日 15:00-16:00 举行 2023 年半年度业绩 ...

经中国证券监督管理委员会《关于核准西藏卫信康医药股份有限公司首次公开发行股票的 批复》（证监许可〔2017〕1098 号）核准，西藏卫信康医药股份有限公司（以下简称"公司"） 公开发行人民币普通股（A 股）6,300 万股，每股面值人民币 1 元，每股发行价格为人民币 5.53 元，募集资金为人民币 348,390,000.00 元，扣除与发行有关的费用（不含税）人民币 51,354,558.49 元后，募集资金净额为 297,035,441.51 元，款项已由主承销商中信证券股份 有限公司（以下简称"中信证券"）于 2017 年 7 月 17 日汇入公司募集资金监管账户。上述募 集资金到位情况经瑞华会计师事务所（特殊普通合伙）验证，并由其出具瑞华验字第 [2017]01300022 号《验资报告》。 （二） 募集资金以前年度使用金额 证券代码：603676 证券简称：卫信康 公告编号：2023-030 西藏卫信康医药股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律 ...

西藏卫信康医药股份有限公司 独立董事签名: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《上海证券交易所 股票上市规则》等有关法律、法规、规范性文件及《公司章程》的规定,我们作 为西藏卫信康医药股份有限公司(以下称"公司")的独立董事,本着实事求是、 认真负责的态度,基于独立判断的立场,根据公司提供的资料,现就公司第三届 董事会第七次会议审议的有关议案及相关事项发表如下意见: 一、关于公司 2023 年半年度募集资金存放与实际使用情况的独立意见 公司《2023 年半年度募集资金存放与实际使用情况的专项报告》内容真实、 准确、完整,真实、客观的反映了公司 2023年半年度募集资金存放和实际使用 情况,符合中国证监会、上海证券交易所关于上市公司募集资金存放与使用的相 关规定,不存在违规使用募集资金的行为,不存在改变或变相改变募集资金投向 和损害股东利益的情况。因此,我们认可公司《2023年半年度募集资金存放与实 际使用情况的专项报告》的内容。 二、关于公司使用募集资金进行现金管理的独立意见 在不影响募集资金投资项目建设和保证募集资金安全的前提下,公司拟使用 部分暂时闲置募集资金进行现金管理,符合《上海 ...

西藏卫信康医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 证券代码：603676 证券简称：卫信康 公告编号：2023-031 现金管理额度：最高额度不超过人民币 3,000.00 万元（含 3,000.00 万 元）。 委托理财品种：仅限于安全性高、流动性好的保本型理财产品或存款类 产品。 履行的审议程序：西藏卫信康医药股份有限公司（以下简称"公司"） 于 2023 年 8 月 22 日召开第三届董事会第七次会议、第三届监事会第七次会议， 分别审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》。公司独立 董事发表了同意的独立意见，该议案无需提交公司股东大会审议。 特别风险提示：尽管公司及全资子公司拟购买的理财产品或存款类产品 为安全性高、流动性好的保本型产品，但仍不排除因市场波动、宏观经济及金融 政策变化、操作风险等原因引起的影响收益的情况。 一、 委托理财概况 （一） 委托理财目的 为提高募集资金使用效率，合理利用闲置募集资金，在不影响募集资金投资 项目建设和保证资金安全性的情况下，公司及全资子公司拟对部分闲置募集资金 进行现金管理，以期增加资金收益，更好的实现公司资金的保值增值，保障 ...

中信证券股份有限公司关于西藏卫信康医药股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为西藏 卫信康医药股份有限公司（以下简称"卫信康"或"公司"）首次公开发行股票 并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 股票上市规则》《上市公司监管指引第2号——上市公司募集资金管理和使用的 监管要求》《上海证券交易所上市公司自律监管指引第1号——规范运作》等有 关规定，就卫信康拟使用暂时闲置募集资金进行现金管理的事项进行了审慎核查， 并出具核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准西藏卫信康医药股份有限公司首次公 开发行股票的批复》（证监许可〔2017〕1098 号）核准，西藏卫信康医药股份有 限公司公开发行人民币普通股（A 股）6,300 万股，每股面值人民币 1 元，每股 发行价格为人民币 5.53 元，募集资金为人民币 348,390,000.00 元，扣除与发行有 关的费用（不含税）人民币 51,354,558.49 元后，募集资金净额为 297,035,441.51 元，款项已由主承 ...

证券代码：603676 证券简称：卫信康 公告编号：2023-027 西藏卫信康医药股份有限公司 关于收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 获得补助金额：2023 年 1 月 18 日至 2023 年 8 月 14 日，西藏卫信康医 药股份有限公司（以下简称"公司"）及全资子公司累计收到与收益相关的政府 补助共计 4,298.54 万元。 当期损益的影响：公司及全资子公司本次累计获得的与收益相关的政府 补助 4,298.54 万元，其中 4,117.89 万元计入营业外收入，180.65 万元计入其 他收益，将对公司 2023 年度的净利润产生一定影响。鉴于公司 2023 年数据未经 审计，具体的会计处理及其对公司相关财务数据的影响将以会计师事务所年度审 计确认后的结果为准。 一、 获得补助的基本情况 （一） 获得补助概况 自 2023 年 1 月 18 日至 2023 年 8 月 14 日，公司及全资子公司累计收到与 收益相关的政府补助 4,298.54 万元（未经审计），占公司 ...

证券代码：603676 证券简称：卫信康 公告编号：2023-026 西藏卫信康医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 西藏卫信康医药股份有限公司（以下简称"公司"）于近日收到中信证券股份有限 公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》，中信证券作为公司 2017年首次公开发行A股股票项目的保荐机构，持续督导期至2019年12月31日止，公司 首次公开发行A股股票的持续督导期已届满。鉴于本次发行股票的募集资金尚未使用完 毕，中信证券仍对募集资金使用情况继续履行持续督导责任。原委派持续督导保荐代表 人罗耸先生因工作变动原因，不再负责公司持续督导工作，为保证持续督导工作的有序 进行，中信证券已授权保荐代表人王琦先生（简历附后）接替罗耸先生担任公司持续督 导期间的保荐代表人，继续履行持续督导职责。 本次变更不影响中信证券对公司的持续督导工作。本次保荐代表人变更后，公司首 次公开发行股票的持续督导保荐代表人为王栋先生和王琦先生。 公司董事会对罗耸先生在持续督 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 350,378,358.40, representing an increase of 11.13% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 60,246,349.21, reflecting a significant increase of 54.82% year-on-year[5]. - Basic earnings per share were CNY 0.14, which is a 55.56% increase from the same period last year[5]. - The total comprehensive income for Q1 2023 was CNY 61,688,708.37, compared to CNY 43,005,260.12 in Q1 2022, reflecting an increase of 43.4%[18]. - The net profit attributable to the parent company for Q1 2023 was CNY 60,246,349.21, an increase from CNY 38,912,971.65 in Q1 2022, representing a growth of 54.5%[18]. Cash Flow - The net cash flow from operating activities reached CNY 50,520,885.53, marking a substantial increase of 91.09% compared to the previous year[5]. - Cash inflows from operating activities for Q1 2023 totaled CNY 372,965,931.43, compared to CNY 298,546,465.92 in Q1 2022, marking an increase of 24.9%[19]. - The net cash flow from operating activities for Q1 2023 was CNY 50,520,885.53, up from CNY 26,438,423.95 in Q1 2022, representing a growth of 91.0%[19]. - Cash inflows from investment activities in Q1 2023 were CNY 638,457,387.79, compared to CNY 433,068,142.09 in Q1 2022, an increase of 47.5%[20]. - The company reported a total cash outflow from financing activities of CNY 957,506.60 in Q1 2023, compared to CNY 2,575,262.17 in Q1 2022, indicating a decrease of 62.8%[20]. Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 1,732,917,426.72, up 4.10% from the end of the previous year[6]. - The total liabilities as of March 31, 2023, were ¥446,568,986.01, slightly up from ¥444,132,719.59 at the end of 2022[14]. - The company's cash and cash equivalents decreased to ¥378,031,020.37 from ¥519,321,896.55 at the end of 2022, a decline of 27.2%[12]. - The total non-current liabilities amounted to approximately $32.3 million, slightly down from $33.0 million[25]. - Current liabilities reached approximately $411.8 million, with accounts payable constituting $236.9 million[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,226[9]. - The largest shareholder, Tibet Weixin Kang Investment Management Co., Ltd., held 47.17% of the shares, amounting to 205,248,960 shares[9]. - Shareholders' equity attributable to the parent company was CNY 1,286,348,440.71, an increase of 5.39% compared to the previous year[6]. - Shareholders' equity stood at approximately $1.221 billion, with retained earnings of approximately $392.9 million[25]. Research and Development - Research and development expenses in Q1 2023 amounted to ¥17,089,273.70, compared to ¥11,045,443.22 in Q1 2022, indicating a growth of 54.7%[17]. - The company reported a total of $38.1 million in development expenditures, consistent with the previous period[24]. Accounting Changes - The company implemented new accounting standards starting in 2023, affecting the initial recognition of deferred tax assets and liabilities[21].

Financial Performance - The company's operating revenue for 2022 was CNY 1,398,543,027.72, representing a year-on-year increase of 35.31% compared to CNY 1,033,622,524.77 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 176,958,679.06, an increase of 84.50% from CNY 95,911,098.26 in the previous year[22]. - The net cash flow from operating activities was CNY 246,153,584.39, reflecting a 44.21% increase compared to CNY 170,688,769.46 in 2021[23]. - The total assets of the company at the end of 2022 were CNY 1,664,718,174.54, which is an 11.31% increase from CNY 1,495,569,265.97 at the end of 2021[23]. - The net assets attributable to shareholders of the listed company increased to CNY 1,220,585,454.95, a growth of 14.37% from CNY 1,067,264,112.89 in the previous year[23]. - The company's operating revenue for 2022 reached RMB 1.399 billion, representing a year-on-year increase of 35.31%[32]. - Net profit attributable to shareholders increased by 84.50% year-on-year, amounting to RMB 177 million, while the net profit excluding non-recurring gains and losses rose by 90.95% to RMB 155 million[25][32]. - Basic and diluted earnings per share increased by 78.26% to RMB 0.41, and the basic earnings per share after excluding non-recurring gains and losses rose by 89.47% to RMB 0.36[24][25]. - The weighted average return on equity increased by 6.11 percentage points to 15.55%[24]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.35 per 10 shares to all shareholders, pending approval at the shareholders' meeting[5]. - The company declared a cash dividend of CNY 102,262,952.50, which represents 57.79% of the net profit attributable to ordinary shareholders in the consolidated financial statements[158]. - The cash dividend per 10 shares is CNY 2.35, with no stock bonus or capital increase from capital reserves[158]. - The company distributed cash dividends of 1.6 yuan per 10 shares, totaling 69,747,040 yuan (including tax) based on a total share capital of 435,919,000 shares[155]. Market and Sales Performance - The sales revenue of the multi-vitamin injection product reached RMB 182 million, a significant increase of 232.17%[33]. - The market terminal sales of trace element injection reached 866 million CNY, a year-on-year increase of 14.62%, with a market share of 15.48% in public medical institutions[34]. - The pediatric multivitamin injection achieved sales revenue of 45 million CNY in 2022, representing a year-on-year growth of 52.97%[34]. - The company has completed bidding and listing in 30 provincial administrative regions for its multi-vitamin injection, maintaining over 80% market share in similar products[33]. - The company has strengthened its sales channel construction and academic promotion efforts to support sales growth[33]. - The self-produced sales model generated ¥406,404,654.86 in revenue, with a gross margin of 91.29%[70]. - The cooperative sales model contributed ¥991,909,015.06, with a gross margin of 36.77%[70]. Research and Development - The company has over 30 ongoing research projects, with three products expected to receive approval in 2023[36]. - The company is actively enhancing its R&D capabilities, focusing on high-difficulty and high-barrier products, and has initiated the construction of a new laboratory in Nanjing[35]. - The company has received acceptance for the registration applications of five products, including dopamine hydrochloride injection and various trace element injections[36]. - The company emphasizes quality management and lean production principles, ensuring strict control over all stages from R&D to logistics[37]. - The company is committed to R&D innovation, continuously developing new products with independent intellectual property rights in the fields of vitamins and trace elements[46]. - The company has developed over 30 new product projects, with 14 invention patents and 17 new drug certificates obtained since 2015[62]. - Research and development expenses increased by 90.57% to 72.45 million RMB, indicating a strong focus on innovation[67]. - The company's R&D investment accounted for 5.71% of its operating revenue and 6.55% of its net assets during the reporting period[101]. - The company’s R&D investment is crucial for maintaining its innovative product pipeline and market competitiveness[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors with expertise in accounting, law, and pharmaceuticals, ensuring compliance with legal requirements[126]. - The company has established a modern corporate governance structure that promotes effective operation and protects the interests of all shareholders[125]. - The company maintains a transparent information disclosure system, ensuring all shareholders have equal access to information[128]. - The company has implemented a performance evaluation and incentive mechanism to motivate senior management and employees based on annual performance assessments[127]. - The company has established a compensation and assessment committee to ensure competitive and balanced remuneration[138]. Environmental Responsibility - The company has not experienced any environmental pollution incidents during the reporting period and has not faced any administrative penalties related to environmental protection[180]. - The company has implemented a detailed environmental management system and performance assessment criteria, integrating environmental management into daily operations[180]. - The company has committed to reducing carbon emissions but did not disclose specific measures or results during the reporting period[181]. - The company has focused on optimizing production processes and enhancing material recycling to minimize waste and emissions[180]. - The company has conducted regular fire safety inspections to eliminate fire hazards and ensure the normal operation of fire safety facilities[180]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[7]. - The company acknowledges potential risks from policy changes in the pharmaceutical industry, which may impact operational models and strategies[120]. - The company faces market risks related to drug price adjustments due to regulatory controls, which may negatively impact profitability over the long term[122]. - The company has a significant number of products in development, with a focus on establishing effective risk assessment and prevention mechanisms in its R&D processes[123]. Strategic Initiatives - The company is committed to innovation-driven strategies, optimizing product layout and structure, and enhancing R&D talent retention[35]. - The company is actively seeking international market opportunities for its core products to drive growth[118]. - The company plans to expand its research and development capabilities with the construction of the Jiangsu Zhongwei Kang R&D Center[86]. - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[133].